Letermovir for Cytomegalovirus Prophylaxis in Heart Transplant Recipients (WTC 2025) - Jul 30, 2025 - Abstract #P2.04.1; Pres time: Aug 4, 2025; 03:30 PM - 04:30 PM; Location: Exhibit Hall AB; "One in 10 patients (10%) developed low-level, non-clinically significant CMV DNAemia during letermovir prophylaxis and switched to ganciclovir. Letermovir was well tolerated with no clinically evident adverse events; however, one patient developed CMV DNAemia during prophylaxis. Close monitoring for breakthrough CMV and calcineurin inhibitor levels is necessary. Further prospective studies are warranted."
Clinical • Cytomegalovirus Infection • Infectious Disease • Transplantation
|
|
T. Sato 1; S. Takenaka 2; M. Ikura 1; T. Iwanaga 1; H. Mochizuki 1; R. Shiomura 3; T. Watanabe 1; T. Nagai 2; S. Fukushima 1; S. Wakasa 2; T. Anzai 2; Y. Tsukamoto 1
|